SynbiCITE finances Prokarium's work toward STD vaccine
The funds are dedicated to a project for finishing the pre-clinical development of a novel Chlamydia vaccine.
"The new vaccine uses synthetic biology to make the first safe and effective Chlamydia vaccine since the 1960s when conventional methods revealed unacceptable side effects and clinical efforts were abandoned,” Prokarium CEO Ted Fjällman said. “We have produced a carrier in the form of a re-engineered strain of Salmonella containing the blueprint for the vaccine. It will be taken orally and as it enters through the person's gut lining it is naturally engulfed by the body's own immune cells and only then triggered to produce the active vaccine exactly where it is needed and without side effects in other parts of the body. This is a uniquely suitable solution and has already raised interest from big pharmaceutical companies."
SynbiCITE CEO Steve Chambers said the need for a Chlamydia vaccine is significant and the potential for this approach both for Chlamydia and as a model for treating other infections is very encouraging.
"This SynbiCITE funding allows us to test a vaccine against one of the world's most serious sexually transmitted infections,” Steve Chatfield, chairman of Prokarium and former executive director of the U.K. Health Protection Agency, said. “This endeavor, among others, has also enabled us to attract Dr. Allan Jarvis -- former vice president of corporate development of Sanofi Pasteur -- to Prokarium's Board of Directors. Prokarium is now well set up to work with the best of the best in the vaccine arena."